Trial record 2 of 9 for:    ibrutinib waldenstrom

Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified November 2015 by Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Steven P. Treon, MD, PhD, Dana-Farber Cancer Institute Identifier:
First received: November 11, 2015
Last updated: November 12, 2015
Last verified: November 2015
This research study is studying a drug called ibrutinib as a possible treatment for untreated Waldenstrom's Macroglobulinemia (WM).

Condition Intervention Phase
Waldenstrom's Macroglobulinemia
Drug: Ibrutinib
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

Resource links provided by NLM:

Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • Major Response Rate [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To asses the proportion of participants with a PR (50% reduction or more in serum IgM) or better.

  • Best Overall Response Rate [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To asses the proportion of participants with an MR (25% reduction or more in serum IgM) or better.

Secondary Outcome Measures:
  • Safety and tolerability of ibrutinib assessed by Adverse events considered to be related to the study drug will be recorded. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Response rates by genetic variants [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Identifying genomic variants that are determinants of response and response duration

  • Duration of response [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: November 2015
Estimated Study Completion Date: February 2023
Estimated Primary Completion Date: February 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ibrutinib
This is single arm, open label, Phase II, single center study designed to evaluate the safety and efficacy of ibrutinib in previously untreated WM patients. Treatment will be administered in 4-week cycles, and participants will receive treatment for up to 48 cycles. Treatment will be comprised of ibrutinib at 420 mg per day by oral administration.
Drug: Ibrutinib
Other Names:
  • Imbruvica
  • PCI-32765

Detailed Description:

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.

The FDA (the U.S. Food and Drug Administration) has approved ibrutinib as a form of treatment for the patient specific disease.

Ibrutinib has been under investigation in research studies in participants with recurrent B-cell lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and prolymphocytic leukemia, and WM. In a study of ibrutinib in relapsed/refractory WM patients, response rates were high and the treatment was well tolerated.

The prior studies suggest that ibrutinib may be a useful treatment strategy for untreated WM patients. This study will test the safety and efficacy of ibrutinib as an option for untreated WM patients. The study will also conduct genomic sequencing of malignant WM cells before the start of treatment, and 6, 12, 24, 36 and 48 months afterwards. Genomic sequencing is the analysis of the entire DNA structure from tumor and normal cells. The purpose of this sequencing is to study which genetic changes effect how ibrutinib works. The results of these studies could also help in better understanding the course of WM disease, and be applicable to the development of other effective drug treatments.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia and meeting criteria for treatment using consensus panel criteria from the Second International Workshop on Waldenstrom's macroglobulinemia (Kyle et al, 2003).
  • Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of ≥ 2 times the upper limit of normal is required.
  • Age ≥ 18 years.
  • ECOG performance status ≤2 (see Appendix A.).
  • Participants must have normal organ and marrow function as defined below:

    • Absolute neutrophil count ≥ 1,000/μL
    • Platelets ≥ 50,000/μL
    • Hemoglobin ≥ 8 g/dL
    • Total bilirubin ≤ 2.0. mg/dL or < 2.5 mg/dL if attributable to hepatic infiltration by neoplastic disease or Gilbert's syndrome.
    • AST (SGOT) and ALT (SGPT) ≤ 2.5 X institutional upper limit of normal
    • Estimated Creatinine Clearance ≥30ml/min
  • Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin.
  • Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or have or will have complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) while participating in the study; and 2) for at least 28 days after discontinuation from the study. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. FCBP must be referred to a qualified provider of contraceptive methods if needed.
  • Able to adhere to the study visit schedule and other protocol requirements.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Both men and women of all races and ethnic groups are eligible for this trial.

Exclusion Criteria:

  • Prior systemic therapy for WM
  • Any serious medical condition, laboratory abnormality, uncontrolled intercurrent illness, or psychiatric illness/social condition that would prevent the participant from signing the informed consent form.
  • Concurrent use of any other anti-cancer treatments or any other investigational agents.
  • Concomitant use of warfarin or other Vitamin K antagonists.
  • Concomitant treatment with strong CYP3A4/5 inhibitor.
  • Any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  • Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion could interfere with the absorption or metabolism of ibrutinib.
  • Known CNS lymphoma.
  • Concomitant use of medication known to cause QT prolongation.
  • Currently active, clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification, or history of myocardial infarction, unstable angina or acute coronary syndrome within 6 months of screening.
  • Malabsorption, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
  • Known history of Human Immunodeficiency Virus (HIV), active infection with Hepatitis B Virus (HBV), and/or Hepatitis C Virus (HCV). Subjects who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded.
  • Lactating or pregnant women.
  • Inability to swallow capsules.
  • History of non-compliance to medical regimens.
  • Unwilling or unable to comply with the protocol.
  • Major surgery within 4 weeks of first dose of study drug.
  • No active infections requiring systemic therapy.
  • Known bleeding disorders with the exception of acquired Von Willebrand Disorder suspected on the basis of WM.
  • History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02604511

Contact: Steven P Treon, MD, PhD 617-632-2681

United States, Massachusetts
Dana-Farber Cancer Institute Not yet recruiting
Boston, Massachusetts, United States, 02215
Contact: Steven P Treon, MD, PhD    617-632-2681      
Principal Investigator: Steven P. Treon, MD, MA, PhD         
Massacusetts General Hospital Not yet recruiting
Boston, Massachusetts, United States, 02114
Contact: Elizabeth O'Donnell, MD    617-724-4000      
Principal Investigator: Elizabeth O'Donnell, MD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
Principal Investigator: Steven P Treon, MD, PhD Dana-Farber Cancer Institute
  More Information

No publications provided

Responsible Party: Steven P. Treon, MD, PhD, Dana-Farber Cancer Institute Identifier: NCT02604511     History of Changes
Other Study ID Numbers: 15-359
Study First Received: November 11, 2015
Last Updated: November 12, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Dana-Farber Cancer Institute:
Waldenstrom's Macroglobulinemia

Additional relevant MeSH terms:
Waldenstrom Macroglobulinemia
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Neoplasms, Plasma Cell
Vascular Diseases processed this record on November 30, 2015